SOPHiA GENETICS SA (NASDAQ:SOPH) Receives Average Rating of "Hold" from Analysts

Key Points

• Analysts have a consensus “Hold” rating on SOPHiA GENETICS, with three buys, one hold and one sell among five covering firms. The average 12-month price target is $10.00, while recent targets range from $9.00 to $14.00.
• The company reported quarterly revenue of $23.31 million, above estimates of $21.72 million, but its adjusted loss of $0.26 per share was wider than the expected $0.21 loss. Analysts forecast a full-year loss of approximately $0.77 per share.
• SOPH shares opened at $8.20, near their 52-week high of $8.98, while insiders sold 217,745 shares worth about $1.56 million over the past quarter. Institutional investors own 31.59% of the company.

Shares of SOPHiA GENETICS SA (NASDAQ:SOPH - Get Free Report) have been assigned a consensus recommendation of "Hold" from the five research firms that are covering the stock, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, one has given a hold recommendation and three have assigned a buy recommendation to the company. The average 12 month target price among brokers that have updated their coverage on the stock in the last year is $10.00.

SOPH has been the subject of a number of analyst reports. BTIG Research increased their price target on SOPHiA GENETICS from $8.00 to $9.00 and gave the company a "buy" rating in a report on Wednesday, August 5th. Zacks Research raised SOPHiA GENETICS to a "hold" rating in a research report on Tuesday, July 21st. Weiss Ratings reiterated a "sell (d-)" rating on shares of SOPHiA GENETICS in a research note on Friday, July 17th. Finally, HC Wainwright raised their price target on shares of SOPHiA GENETICS from $12.00 to $14.00 and gave the stock a "buy" rating in a research report on Wednesday, August 5th.

SOPHiA GENETICS Price Performance

SOPH stock opened at $8.20 on Tuesday. The firm has a market cap of $687.90 million, a P/E ratio of -7.13 and a beta of 0.95. The company has a debt-to-equity ratio of 0.58, a quick ratio of 2.55 and a current ratio of 2.69. SOPHiA GENETICS has a 1 year low of $3.75 and a 1 year high of $8.98. The stock has a 50-day simple moving average of $7.78 and a 200-day simple moving average of $6.10.

SOPHiA GENETICS (NASDAQ:SOPH - Get Free Report) last released its quarterly earnings results on Wednesday, August 5th. The company reported ($0.26) EPS for the quarter, missing the consensus estimate of ($0.21) by ($0.05). The company had revenue of $23.31 million for the quarter, compared to analyst estimates of $21.72 million. SOPHiA GENETICS had a negative return on equity of 132.47% and a negative net margin of 93.86%. On average, equities analysts predict that SOPHiA GENETICS will post -0.77 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, Chairman Jurgi Camblong sold 24,381 shares of the business's stock in a transaction dated Monday, July 20th. The shares were sold at an average price of $6.29, for a total value of $153,356.49. Following the completion of the sale, the chairman owned 3,512,822 shares of the company's stock, valued at approximately $22,095,650.38. The trade was a 0.69% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Zhenyu Xu sold 17,000 shares of the company's stock in a transaction dated Friday, August 7th. The shares were sold at an average price of $7.29, for a total transaction of $123,930.00. Following the completion of the sale, the insider owned 590,887 shares in the company, valued at approximately $4,307,566.23. This trade represents a 2.80% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 217,745 shares of company stock worth $1,560,269 over the last quarter. 4.88% of the stock is currently owned by insiders.

Institutional Trading of SOPHiA GENETICS

Several institutional investors and hedge funds have recently bought and sold shares of SOPH. Maven Securities LTD acquired a new position in shares of SOPHiA GENETICS in the 2nd quarter worth approximately $866,000. AXQ Capital LP bought a new position in SOPHiA GENETICS during the second quarter worth $119,000. AWM Investment Company Inc. bought a new position in SOPHiA GENETICS during the second quarter worth $9,809,000. Hennion & Walsh Asset Management Inc. acquired a new position in SOPHiA GENETICS in the second quarter worth $567,000. Finally, Royal Bank of Canada increased its stake in SOPHiA GENETICS by 3,130.2% during the first quarter. Royal Bank of Canada now owns 19,381 shares of the company's stock valued at $96,000 after purchasing an additional 18,781 shares during the last quarter. Institutional investors and hedge funds own 31.59% of the company's stock.

About SOPHiA GENETICS

SOPHiA GENETICS is a healthcare technology company that develops cloud-based data analytics solutions for the life sciences and healthcare industries. Its platform is designed to help organizations analyze and interpret complex genomic and multimodal data to support more informed clinical and research decisions.

The company's principal offering, the SOPHiA DDM platform, combines data management, analytics and artificial intelligence capabilities. It supports applications including cancer genomics, hereditary disease analysis, reproductive health and other areas of precision medicine.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.